Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Goshen, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Terre Haute, IN
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Terre Haute, IN
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Fairway, KA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Scarborough, ME
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Scarborough, ME
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Burlington, MA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Billings, MT
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Lincoln, NE
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Farmington, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Farmington, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Las Cruces, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Las Cruces, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Santa Fe, NM
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Rochester, NY
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Durham, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Greensboro, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Greensboro, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
High Point, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Washington, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Washington, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Columbus, OH
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Toledo, OH
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Dunmore, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Dunmore, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Media, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Media, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Charleston, SC
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Corpus Christi, TX
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Houston, TX
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Madison, WI
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Wauwatosa, WI
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Wauwatosa, WI
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Clinical Research Facility
mi
from
Elizabethtown, KY
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
Investigational Site
mi
from
Manasquan, NJ
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
Investigational Site
mi
from
Manasquan, NJ
Click here to add this to my saved trials
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/8/2016
mi
from
Edmonton,
Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer
A Randomized Phase II Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/8/2016
mi
from
Edmonton,
Click here to add this to my saved trials
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated:  1/8/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated: 1/8/2016
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated:  1/8/2016
Georgia Cancer Center
mi
from
Atlanta, GA
Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer
Phase II Study of a Novel Taxane (Cabazitaxel-XRP6258) in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Status: Enrolling
Updated: 1/8/2016
Georgia Cancer Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated:  1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Status: Enrolling
Updated: 1/8/2016
National Cacner Institue
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
University of California, Los Angeles Institute of Urologic Oncology
mi
from
Los Angeles, CA
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
University of California, Los Angeles Institute of Urologic Oncology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Florida Cancer Specialists-Fort Myers
mi
from
Fort Myers, FL
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Florida Cancer Specialists-Fort Myers
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Lakeland Regional Cancer Center
mi
from
Lakeland, FL
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Southern Illinois University School of Medicine
mi
from
Springfield, IL
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Southern Illinois University School of Medicine
mi
from
Springfield, IL
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Comprehensive Cancer Centers of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated:  1/8/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone
Status: Enrolling
Updated: 1/8/2016
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials